Antje Danielczyk

509 total citations
23 papers, 361 citations indexed

About

Antje Danielczyk is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Antje Danielczyk has authored 23 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 17 papers in Radiology, Nuclear Medicine and Imaging and 13 papers in Immunology. Recurrent topics in Antje Danielczyk's work include Monoclonal and Polyclonal Antibodies Research (17 papers), Glycosylation and Glycoproteins Research (15 papers) and Galectins and Cancer Biology (7 papers). Antje Danielczyk is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (17 papers), Glycosylation and Glycoproteins Research (15 papers) and Galectins and Cancer Biology (7 papers). Antje Danielczyk collaborates with scholars based in Germany, Switzerland and Italy. Antje Danielczyk's co-authors include Steffen Goletz, Uwe Karsten, Renate Stahn, Arseni Markoff, Volker Gerke, Ursula Rescher, Anja Löffler, Angela Märten, Peter Ravn and Peter Astrup Christensen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Antje Danielczyk

22 papers receiving 340 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Antje Danielczyk Germany 9 277 182 166 105 41 23 361
Anca Clabbers United States 7 269 1.0× 271 1.5× 112 0.7× 100 1.0× 25 0.6× 9 402
Angéla Virone-Oddos France 11 185 0.7× 81 0.4× 89 0.5× 144 1.4× 52 1.3× 30 376
Martine Darwish United States 9 232 0.8× 200 1.1× 98 0.6× 173 1.6× 31 0.8× 16 444
Liying Jiang United States 4 268 1.0× 201 1.1× 113 0.7× 75 0.7× 19 0.5× 6 388
Michelle L. VanLith United States 6 251 0.9× 107 0.6× 218 1.3× 87 0.8× 22 0.5× 6 360
Glòria Tabarés Germany 7 288 1.0× 71 0.4× 106 0.6× 49 0.5× 58 1.4× 10 352
Amparo Macías Cuba 7 231 0.8× 176 1.0× 184 1.1× 216 2.1× 12 0.3× 15 437
Weichen Qi China 3 337 1.2× 122 0.7× 129 0.8× 74 0.7× 101 2.5× 6 417
Sandra Klausing Germany 7 374 1.4× 56 0.3× 205 1.2× 81 0.8× 47 1.1× 11 450
Sarah Petrie United States 5 206 0.7× 45 0.2× 231 1.4× 115 1.1× 26 0.6× 5 410

Countries citing papers authored by Antje Danielczyk

Since Specialization
Citations

This map shows the geographic impact of Antje Danielczyk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antje Danielczyk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antje Danielczyk more than expected).

Fields of papers citing papers by Antje Danielczyk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antje Danielczyk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antje Danielczyk. The network helps show where Antje Danielczyk may publish in the future.

Co-authorship network of co-authors of Antje Danielczyk

This figure shows the co-authorship network connecting the top 25 collaborators of Antje Danielczyk. A scholar is included among the top collaborators of Antje Danielczyk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antje Danielczyk. Antje Danielczyk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Danielczyk, Antje, et al.. (2023). Targeting a cancer-specific LYPD3 glycoform for tumor therapy. SHILAP Revista de lepidopterología. 3. 1 indexed citations
3.
Danielczyk, Antje, et al.. (2022). Abstract 316: Carbohydrate-dependent protein binding antibodies with superior tumor-specificity. Cancer Research. 82(12_Supplement). 316–316. 1 indexed citations
4.
Neumann, Theresa, et al.. (2022). 1347 Targeting of a cancer-associated LYPD3 glycoform for tumor therapy. Regular and Young Investigator Award Abstracts. A1398–A1398. 2 indexed citations
5.
Stech, Marlitt, et al.. (2022). Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and E. coli Cell-Free Systems. International Journal of Molecular Sciences. 23(22). 13697–13697. 6 indexed citations
6.
Lischke, Timo, et al.. (2021). 712 Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties. SHILAP Revista de lepidopterología. A741–A741. 1 indexed citations
7.
Flechner, Anke, Anja Löffler, Shin‐Ichiro Nishimura, et al.. (2019). Cluster binding studies with two anti-Thomsen-Friedenreich (anti-core-1, CD176, TF) antibodies: Evidence for a multiple TF epitope. International Immunopharmacology. 72. 186–194. 3 indexed citations
8.
Fiedler, Walter, Herbert Stoeger, Antonella Perotti, et al.. (2018). Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours. ESMO Open. 3(4). e000381–e000381. 14 indexed citations
9.
Fiedler, Walter, Sara Cresta, Henning Schulze‐Bergkamen, et al.. (2018). Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. ESMO Open. 3(2). e000303–e000303. 12 indexed citations
10.
11.
Fiedler, Walter, Cristiana Sessa, Luca Gianni, et al.. (2013). First-in-human phase I study of CetuGEX, a novel anti-EGFR monoclonal antibody (mAb) with optimized glycosylation and antibody dependent cellular cytotoxicity.. Journal of Clinical Oncology. 31(15_suppl). 3008–3008. 1 indexed citations
12.
Goletz, Steffen, et al.. (2010). GlycoOptimization for Fully Human and Largely Improved Biopharmaceutical Antibodies and Proteins. 2 indexed citations
13.
Christensen, Peter Astrup, Antje Danielczyk, Peter Ravn, et al.. (2008). Modifying Antibody Specificity by Chain Shuffling of VH / VL between Antibodies with Related Specificities. Scandinavian Journal of Immunology. 69(1). 1–10. 8 indexed citations
14.
Christensen, Peter Astrup, Antje Danielczyk, Peter Ravn, et al.. (2007). A Monoclonal Antibody to Lewis Y/Lewis b Revealing Mimicry of the Histone H1 to Carbohydrate Structures. Scandinavian Journal of Immunology. 65(4). 362–367. 5 indexed citations
15.
Ravn, Peter, et al.. (2007). The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvs. Cancer Immunology Immunotherapy. 56(9). 1345–1357. 11 indexed citations
16.
Danielczyk, Antje, Renate Stahn, Anja Löffler, et al.. (2006). PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunology Immunotherapy. 55(11). 1337–1347. 108 indexed citations
17.
Ravn, Peter, Antje Danielczyk, Kim B. Jensen, et al.. (2004). Multivalent scFv Display of Phagemid Repertoires for the Selection of Carbohydrate-specific Antibodies and its Application to the Thomsen–Friedenreich Antigen. Journal of Molecular Biology. 343(4). 985–996. 36 indexed citations
18.
Christensen, Peter Astrup, Antje Danielczyk, Renate Stahn, & Steffen Goletz. (2004). Simple separation of DNA in antibody purification. Protein Expression and Purification. 37(2). 468–471. 3 indexed citations
19.
Goletz, Steffen, et al.. (2003). Thomsen-Friedenreich Antigen: The “Hidden” Tumor Antigen. Advances in experimental medicine and biology. 535. 147–162. 38 indexed citations
20.
Rescher, Ursula, Antje Danielczyk, Arseni Markoff, & Volker Gerke. (2002). Functional Activation of the Formyl Peptide Receptor by a New Endogenous Ligand in Human Lung A549 Cells. The Journal of Immunology. 169(3). 1500–1504. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anca Clabbers Breakdown of academic impact, for papers by Angéla Virone-Oddos Breakdown of academic impact, for papers by Martine Darwish Breakdown of academic impact, for papers by Liying Jiang Breakdown of academic impact, for papers by Michelle L. VanLith Breakdown of academic impact, for papers by Glòria Tabarés Breakdown of academic impact, for papers by Amparo Macías Breakdown of academic impact, for papers by Weichen Qi Breakdown of academic impact, for papers by Sandra Klausing Breakdown of academic impact, for papers by Sarah Petrie
Rankless by CCL
2026